ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Histocompatibility"

  • 2019 American Transplant Congress

    “Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA

    A. Casillas-Abundis, A. Tambur, A. Shetty, C. D'Agostino, J. R. Leventhal

    Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL

    *Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…
  • 2019 American Transplant Congress

    Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match

    Q. Xu1, A. House2, S. Leckie1, L. Gunaratnam2, P. Luke3, A. Jevnikar2

    1Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, 2Medicine, Western University, London, ON, Canada, 3Surgery, Western University, London, ON, Canada

    *Purpose: Despite implementation of virtual cross matches, flow cytometry cross matches (FCXM) are still used by many transplant centers to determine immunological risk prior to…
  • 2019 American Transplant Congress

    Correlation of Crossmatch Predictions with Actual Results and Clinical Outcomes

    R. Forbes1, B. Concepcion1, S. Fossey2

    1Vanderbilt University Medical Center, Nashville, TN, 2Dialysis Clinic, Inc, Nashville, TN

    *Purpose: Flow cytometry crossmatching (FXM) is recognized as a valuable tool to assess immunological risk prior to renal transplantation. The increased resolution in HLA typing…
  • 2019 American Transplant Congress

    Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation

    S. Park1, S. Lee1, J. Hwang1, J. Ryu2, T. Koo2, C. Ahn3, J. Yang4

    1Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, 2Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, 4Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of

    *Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…
  • 2019 American Transplant Congress

    Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation

    J. D. Motter1, K. Jackson1, S. Bae1, X. Luo1, J. Long1, L. Kucirka1, B. Orandi2, A. Muzaale1, J. Coresh1, J. Garonzik-Wang1, D. Segev1, A. Massie1

    1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL

    *Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…
  • 2019 American Transplant Congress

    Towards Human Leukocyte Antigen Immunogenicity Assessment at the Individual Patient Level

    H. Copley1, H. McDowell2, D. Pinelli2, A. R. Tambur2, V. Kosmoliaptsis1

    1Department of Surgery, University of Cambridge, Cambridge, United Kingdom, 2Department of Surgery, Feinberg School of Medicine, Comprehensive Transplant Center, Northwestern University, Chicago, IL

    *Purpose: Allorecognition of donor HLA and induction of humoral alloimmunity is a major cause of graft loss after solid-organ transplantation. Current approaches to study molecular…
  • 2019 American Transplant Congress

    Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates

    H. Sweiss1, J. Lyons1, D. Ranch2, K. Hitchman2, E. Kincaide1, B. Crowther1

    1University Health System, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 2University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX

    *Purpose: Evaluate anti-HLA antibody (Ab) emergence after catch-up vaccinations in pediatric kidney transplant candidates (PKTC).*Methods: A single center retrospective review of PKTC 25% from baseline,…
  • 2019 American Transplant Congress

    The Effect Of Exclusive Virtual Crossmatch To Allocate Deceased Donor Kidney Transplant On Cold Ischemia Time And Acute Rejection

    E. Abuhelaiqa1, M. Alkadi1, S. Thappy1, S. Saleh2, J. Mahmoud3, M. Jarman3, O. Fituri1, M. Elkhalifa4, J. Wadström3, H. Al-Malki1

    1Medicine-Nephrology, Hamad Medical Corporation, Doha, Qatar, 2Histocompatibility & Immunogenetics Laboratory,, Hamad Medical Corporation, Doha, Qatar, 3Surgery-Transplant, Hamad Medical Corporation, Doha, Qatar, 4Histocompatibility & Immunogenetics Laboratory, Hamad Medical Corporation, Doha, Qatar

    *Purpose: Virtual crossmatch (VXM) using Luminex single antigen bead has significantly improved prediction of an actual negative crossmatch. A negative crossmatch is typically required for…
  • 2019 American Transplant Congress

    Center-Level Variation in HLA-Incompatible Living Donor Kidney Transplantation Outcomes

    K. Jackson1, J. Long1, K. Covarrubias1, J. Motter1, M. Bowring1, J. Chen1, M. Waldram1, B. Orandi2, N. Desai1, A. Massie1, D. Segev1, J. Garonzik-Wang1

    1Johns Hopkins University, Baltimore, MD, 2University of Alabama School of Medicine, Birmingham, AL

    *Purpose: Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these variations, as well as other practice variations, on…
  • 2018 American Transplant Congress

    Rituximab Interference in B-Cell Crossmatch: A Problem Solved

    P. Malvezzi,1 O. Senoussi,2 T. Jouve,1 C. De Palma,2 L. Rostaing,1 B. Bardy,2 D. Masson.2

    1Service de Néphrologie, Dialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France; 2Laboratoire d'Histocompatibilité, EFS Rhone Alpes, Grenoble, France.

    Background: Rituximab is commonly prescribed in ABO- or HLA-incompatible kidney transplantation. When used before transplant it interferes with B lymphocyte complement-dependent crossmatch (CDC CM) or…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences